A Selective RPL15 PROTAC Degrader Enhances Anti-PD-1 Immunotherapy in a Murine Melanoma Tumor Model

RPL15-knockdown B16-F10 melanoma tumors were sensitized to anti-PD-1 antibody, suggesting that RPL15 inhibition may have the potential to improve immune checkpoint inhibitor efficacy.